Oxford, UK – 28 October 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence… Read More
Oxford, UK – 27 August 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2015. Read More
Oxford, UK – 6 August 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2015 on Thursday 27… Read More
Oxford, UK – 23 June 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces that Chief Executive Officer John Dawson will present today at the 2015 JMP… Read More
Oxford, UK – 29 May 2015: Oxford BioMedica plc (LSE: Oxford Biomedica) (“the Group”), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, is scheduled to present at the… Read More
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces the appointment of Daniel Soland as a Non-Executive Director of the Group. Read More
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group” or “Oxford Biomedica”) (LSE:Oxford Biomedica), a leading gene and cell therapy Group, today publishes its interim management statement for the period from 1 January… Read More
Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“the Company”) the leading gene and cell therapy based biopharmaceutical company, today announces that results from the 21 patients in its Phase I study of RetinoStat… Read More
Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE: Oxford Biomedica) (“the Group”), a leading gene and cell therapy group, today announces that Professor Stéphane Palfi MD, PhD has presented a summary of the results from the 12 months… Read More
Oxford, UK – 1 May 2015: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford BioMedica” or the “Group”) a leading gene and cell therapy Group, today announces that it has secured a $50 million loan facility from a subsidiary… Read More
London, UK – 2 April 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, gives notice that copies of the 2014 Annual Report and Accounts and the Notice of… Read More
London, UK – 20 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:Oxford Biomedica), a leading gene and cell therapy company, announces that Dr Paul Blake, Chief Development Officer, will present at the 3… Read More